Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about $64,000 a year.
Similar Stories to Neurocrine Biosciences’ New Drug May Cost Patients Taking Recommended Dose Twice As Much As Expected on Bing News
MarketWatch.com - Top Stories, MarketWatch
Wed, 04/26/2017 - 2:27pm
BING NEWS:
- Study: Access to targeted lung cancer drug is cost-prohibitive globally
Many countries with national health care systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with ...
05/30/2024 - 10:36 am | View Link - Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris ...
05/20/2024 - 5:50 pm | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more